Clinically, high SLC7A11 or GPX4 expression in NPC tumors has been associated with poorer survival and reduced response to radiotherapy or platinum-based chemotherapy, underscoring the central role of this axis in determining treatment outcomes. The gene discussed is GPX4; the disease is nasopharyngeal carcinoma.